Hengrui Medicine has recently been notified by the U.S. Food and Drug Administration (FDA) with a complete response letter concerning the Biologics License Application (BLA) for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma, utilizing a combination of Camrelizumab and Apatinib. The FDA noted in the letter that additional responses are required for the inspection of the relevant production site, though specific reasons were not disclosed. Previously, the application was denied due to deficiencies in the production site inspection and travel restrictions in certain countries. Hengrui Medicine has since addressed these issues and resubmitted the application. This treatment regimen, backed by positive results from an international multicenter Phase III clinical study (CARES-310 study), has already received approval from China's National Medical Products Administration (NMPA) and boasts the longest median overall survival (mOS) research data to date. Hengrui Medicine affirmed that it will maintain close communication with the FDA, take prompt action once the specific reasons are confirmed, and resubmit the application accordingly.
